Featured Research

from universities, journals, and other organizations

International Space Station Research To Study Treatments For Liver Ailments

Date:
January 18, 2002
Source:
National Aeronautics And Space Administration
Summary:
NASA has signed an agreement with StelSys LLC, Baltimore, to fly experiments on the International Space Station that will compare human liver-cell function in space with that on Earth. This research could aid in StelSys' development of treatment for people in need of liver transplants.

NASA has signed an agreement with StelSys LLC, Baltimore, to fly experiments on the International Space Station that will compare human liver-cell function in space with that on Earth. This research could aid in StelSys' development of treatment for people in need of liver transplants.

The research primarily will evaluate how human liver cells process medicine in space and will add to further ground-based research. Space Shuttle Discovery will deliver the research equipment on mission STS- 111 scheduled for launch in May 2002.

"This will be an excellent start for commercial use of space technology," said Dr. Neal Pellis, Chief, Biological Systems Office, at NASA's Johnson Space Center in Houston. "We hope this is the first of many." The agreement to fly experiments in space comes just one year after a groundbreaking licensing agreement between NASA and StelSys intended to explore a new frontier in biotechnology. The agreement focuses on the development of commercial medical products and services using NASA's Bioreactor technology in four areas, including development of a liver-assist device and a method for producing liver-cell biomolecules and metabolites.

"Space is the gold-standard environment for this cutting-edge cell research. Only in space, a true microgravity environment, will we be able to isolate and study each of the individual factors impacting cell function. This will allow us to refine and then optimize ground-based Bioreactor research," said Dr. Fisk Johnson, president of Wisconsin-based Fisk Ventures and co-founder of StelSys.

Utilizing the Bioreactor technology over the past year, StelSys scientists have discovered a unique procedure to accomplish long-term culturing of liver cells, which allows the cells to maintain liver-specific functions for at least a week, compared to only a day using traditional methods. In addition, they have developed a prototype of a novel "bioartificial" liver.

NASA invented the rotating Bioreactor as a way to study the impact of microgravity on cellular growth on Earth and in space. Traditional cell-growth research often produces single-cell, pancake-like cultures which quickly lose normal cell function. The Bioreactor works by gently spinning a fluid medium filled with cells. The spinning motion neutralizes most of gravity's effects, creating a near-weightless environment that allows cells to grow more freely, in a three-dimensional manner.

"StelSys is committed to research with real-world benefit to people. Our recent discoveries could lead to better, earlier drug-candidate screening, which would speed up drug development by pharmaceutical companies, and importantly, to a longer life for the 25,000 people every year waiting for a life-saving liver transplant," said Dr. Paul Silber, president of StelSys. This research is being conducted under an agreement with NASA's Office of Biological and Physical Research, Washington. The office is responsible for basic and applied research using the low-gravity environment of space.

StelSys LLC is a biotechnology research company formed to develop and commercialize real-world applications of the NASA Bioreactor technology. The company maintains a core team of researchers with expertise in cell biology and chemical engineering.

Additional information concerning this research is available via the Internet at:

http://spaceresearch.nasa.gov/


Story Source:

The above story is based on materials provided by National Aeronautics And Space Administration. Note: Materials may be edited for content and length.


Cite This Page:

National Aeronautics And Space Administration. "International Space Station Research To Study Treatments For Liver Ailments." ScienceDaily. ScienceDaily, 18 January 2002. <www.sciencedaily.com/releases/2002/01/020118075705.htm>.
National Aeronautics And Space Administration. (2002, January 18). International Space Station Research To Study Treatments For Liver Ailments. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2002/01/020118075705.htm
National Aeronautics And Space Administration. "International Space Station Research To Study Treatments For Liver Ailments." ScienceDaily. www.sciencedaily.com/releases/2002/01/020118075705.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



    Save/Print:
    Share:

    Free Subscriptions


    Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

    Get Social & Mobile


    Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

    Have Feedback?


    Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
    Mobile: iPhone Android Web
    Follow: Facebook Twitter Google+
    Subscribe: RSS Feeds Email Newsletters
    Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins